Print Page  |  Close Window

Investor Overview

Corporate Profile

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.

Latest News

February 06, 2017

Oncobiologics Announces Term Extension of Series A Warrantsmore >

January 10, 2017

Oncobiologics Issues Remaining Senior Secured Notes and Warrants – Raising an Aggregate $10.0 Millionmore >

December 23, 2016

Oncobiologics Issues $8.35 Million of Senior Secured Notes and Warrants to Acquire 1.9 Million Shares as part of Aggregate $10.0 Million Note and 2.3 Million Warrant Offeringmore >

Upcoming Events

There are currently no events scheduled.